Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Dow
Merck
Johnson and Johnson
McKesson

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

HUMALOG MIX 50/50 KWIKPEN Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Humalog Mix 50/50 Kwikpen, and what generic alternatives are available?

Humalog Mix 50/50 Kwikpen is a drug marketed by Lilly and is included in one NDA. There is one patent protecting this drug.

This drug has sixteen patent family members in twelve countries.

The generic ingredient in HUMALOG MIX 50/50 KWIKPEN is insulin lispro protamine recombinant; insulin lispro recombinant. There are forty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the insulin lispro protamine recombinant; insulin lispro recombinant profile page.

Summary for HUMALOG MIX 50/50 KWIKPEN
Drug patent expirations by year for HUMALOG MIX 50/50 KWIKPEN
Recent Clinical Trials for HUMALOG MIX 50/50 KWIKPEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y SaludPhase 4
Zealand PharmaPhase 2
Beta Bionics, Inc.Phase 2

See all HUMALOG MIX 50/50 KWIKPEN clinical trials

Pharmacology for HUMALOG MIX 50/50 KWIKPEN
Ingredient-typeInsulin
Drug ClassInsulin Analog

US Patents and Regulatory Information for HUMALOG MIX 50/50 KWIKPEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly HUMALOG MIX 50/50 KWIKPEN insulin lispro protamine recombinant; insulin lispro recombinant INJECTABLE;INJECTION 021018-002 Sep 6, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for HUMALOG MIX 50/50 KWIKPEN

Supplementary Protection Certificates for HUMALOG MIX 50/50 KWIKPEN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0792290 PA2004005 Lithuania   Start Trial PRODUCT NAME: INSULIN DETEMIR
0368187 SZ 34/2000 Austria   Start Trial PRODUCT NAME: LANTUS - INSULIN GLARGIN
2597103 CA 2017 00013 Denmark   Start Trial PRODUCT NAME: KOMBINATION AF INSULIN DEGLUDEC OG LIRAGLUTID; NAT. REG. NO/DATE: EU/1/14/947 20140922; FIRST REG. NO/DATE: CH 65041 20140912
2498802 PA2017020,C2498802 Lithuania   Start Trial PRODUCT NAME: INSULINAS GLARGINAS + LIKSISENATIDAS; REGISTRATION NO/DATE: EU/1/16/1157 20170111
0885961 05C0009 France   Start Trial PRODUCT NAME: INSULINE GLULISINE; REGISTRATION NO/DATE IN FRANCE: EU/1/04/258/001 DU 20040927; REGISTRATION NO/DATE AT EEC: EU/1/04/285/001 DU 20040927
0368187 34/2000 Austria   Start Trial PRODUCT NAME: LANTUS - INSULIN GLARGIN; REGISTRATION NO/DATE: EU/1/00/134/001 - EU/1/00/134/007 20000609
2597103 2017/015 Ireland   Start Trial PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; NAT REGISTRATION NO/DATE: EU/1/14/947 20140918; FIRST REGISTRATION NO/DATE: 65041 20140912
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
McKinsey
Merck
Baxter
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.